Products
Ribociclib LEE011 1211441-98-3
1.Inquiries will be replied within 24 hours |
2.We could supply various packages as you required |
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price. |
4.Fast delivery, goods arrive your office within 3 to 5 days |
5.Please click "Inquiry" or "Email" below to get the price |
|
|
||||||
|
C23H30N8O |
|
|||||
|
434.54 |
|
in stock | ||||
|
1211441-98-3 |
|
98%+ |
Introduction
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
Orally bioavailable CDK4/6-selective inhibitor that has been tested in Phase III clinical trials for treatment of advanced breast cancer.
LEE011, as dual CDK4/CDK6 inhibitor, significantly inhibits the growth of 12 of 17 neuroblastoma cell lines with mean IC50 of 307 nM. The growth inhibition of neuroblastoma cell lines is primarily cytostatic and is mediated by a G1 cell-cycle arrest and cellular senescence.
Orally bioavailable CDK4/6-selective inhibitor that has been tested in Phase III clinical trials for treatment of advanced breast cancer.
LEE011, as dual CDK4/CDK6 inhibitor, significantly inhibits the growth of 12 of 17 neuroblastoma cell lines with mean IC50 of 307 nM. The growth inhibition of neuroblastoma cell lines is primarily cytostatic and is mediated by a G1 cell-cycle arrest and cellular senescence.